Abstract Submission Guidelines
ASCPT is currently accepting original abstract submissions. Late-Breaking and Encore Abstract submissions will beaccepted in October 2023.
Failure to comply with these guidelines will prevent an abstract from being considered for presentation during theASCPT 2024 Annual Meeting.
To submit, visit https://www.ascpt.org/Meetings/Annual-Meeting/Call-for-Submissions for a direct link to the abstract
submission site.
DEADLINE: Thursday, September 14, 2023, 4:00 PM ET
COST: Member Submission: $75; Non-Member Submission: $120
Credit card payment is required to complete an abstract submission. ASCPT accepts MasterCard, Visa, and American
Express. Abstract submission fees are non-refundable. ASCPT will not refund the difference for Members who pay theNon-Member abstract fee or for non-members who join ASCPT after abstract submission.
If your employer requires an invoice, please select the “pay by check” option. Payment must be received by September
14, 2023, for your abstract to be reviewed.

SUBMISSION TYPE
Please note that submission of an abstract requires that the presenting author register for the ASCPT 2024 Annual
Meeting and present their poster in-person at the Broadmoor in Colorado Springs, CO.

SUBMISSION FORMAT
All tasks must be completed for the abstract submission to be complete.
1. Abstract
All abstracts must:• Address a clinical, translational, or methodology-based question.
• Apply to clinical pharmacology or translational science.
• Describe original, previously unpublished work at the time of presentation.
• Identify the primary ASCPT Community related to the content of the abstract.
(https://www.ascpt.org/Member-Services/Networks-and-Communities)•Obtain management approval prior to submitting the abstract, if management approval is required fromyour institution. If the abstract is withdrawn after acceptance for reasons such as lack of management
approval, you may be barred from submitting an abstract to ASCPT for a period of one (1) year.

Abstract Content• Abstract Title: Upper case; 200 characters maximum (not including spaces) and 75 words maximum.
• Body: 2,000 character count, not including spaces. Do not include title, author, or institution
information.
o BACKGROUND: State the research objective and the importance of the study being conducted.
o METHODS: Include information on the following aspects of design study:▪ Research Study• Design - Describe the basic study design, e.g., randomized controlled trial, crossover study, etc. The source of all nonstandard reagents needs to be explicitlystated.
• Participants - Indicate number of study subjects and how they were selected;
indicate whether subjects are healthy volunteers.
• Intervention - Report the method of administration and the duration of theintervention. Drug identifier must be included.
• Data collection and analysis - Summarize the method.
▪ Methodology Study• Indicate how data sources were selected, collected, and analyzed.
▪ Literature Survey• Indicate how data sources (literature, drug labels) were selected. Indicate what
data were extracted from each source.
▪ Case Study• Indicate how the case was identified and what data were collected.
o RESULTS: Present the main outcomes of the study. In addition to mean or median values,
provide a measure of variability (such as a confidence interval). Indicate significance of results,
using p-values when appropriate.
▪ This section is omitted for Trials in Progress abstracts.
o CONCLUSION: State that the conclusion is directly supported by the evidence and implications ofthe findings.
▪ This section is omitted for Trials in Progress abstracts.
2. Keywords
Select up to three keywords. One keyword is required for each submission. The list of keywords can be foundwithin the online submission site.
3. Authors
Authorship requires that an individual has contributed in one of the following ways:• Wrote the paper• Designed the research• Performed the research• Analyzed data
• Contributed new reagents or analytical tools
Author names cannot be added or removed from the abstract once it has been submitted, reviewed, and/ or
selected for presentation or published.
At the time of submission, the submitting author must know the following information for all authors:• Author name & email• Author institution•o Do not include specific departments, only institution nameso Can list up to three institutions per author
Authors’ Conflicts of Interest

4. Conflict of Interest
Provide a conflict of interest disclosure on behalf of each author. Examples of conflicts include commercial
sponsorship of research, acceptance of honoraria or consulting fees, and significant stock holdings in a company
connected to the research.
5. Table or Figure
You may include one table or figure with your abstract. Please note that all such files must meet the following
specifications.
• You will be required to upload two versions of your figure/table:o One as a PDF or EPS fileo One as a JPG or PNG fileo No other file types will be acceptedo Please note that both files must be of the same image.
• The image must be no more than 3.35 inches (85 mm) in width.
• Images must be 300 to 600 dpi.
• Tables are limited to no more than 25 cells, with a maximum of 5 rows and 5 columns preferred.
Figure and table files will be included in the format in which they are submitted, so please be sure your filemeets these specifications to ensure legibility and print quality.
6. Additional Abstract Information
Provide the following information:a. Indicate if you plan on utilizing the Poster 2.0 format for your poster, if accepted (more information
below).
b. Indicate if you would like to be contacted if the research could fit within the scope of the ASCPT JournalFamily.
c. Grant ASCPT permission to distribute, duplicate and/or record, in all media formats, theabstract/presentation during the ASCPT Annual Meeting and publish in the abstract supplement toClinical Pharmacology & Therapeutics.
7. Student/Trainee Opportunities
Application for Presidential Trainee Award and Student/Trainee Grant (see trainee abstract information section
for more details).

8. Payment
Member Submission = One or more authors included on the abstract is a member with ASCPT
Non-Member Submission = NO authors included on the abstract are a member with ASCPT at the time ofsubmission
9. Affirmations
Provide your signature and acknowledgement that you have read and understand the listed statements andagree to abide by all terms outlined in the statements.

FAILURE CRITERIAThe following failure criteria apply to all abstract submissions. If the reviewers identify any of these concerns in anabstract, it will not be accepted:
••
•

•
•

Drug identifier is not provided. Abstracts based on surveys of multiple drugs by the US Food and Drug
Administration do not need to include drug identifiers.
o Abstracts need to refer to drugs and therapeutic agents by their accepted generic or chemical name,and do not abbreviate them (a proprietary name may be given only with the first use of the genericname). Code names should be used only when a generic name is not yet available (the chemical nameand a figure giving the chemical structure of the drug is required). Copyright or trade names of drugs
should be capitalized and placed in parentheses after the name of the drug. Names and locations (cityand state in United States; city and country outside United States) of manufacturers of drugs, supplies,
or equipment cited in a manuscript are required to comply with trademark law and should be provided
in parentheses. The official HUGO gene should be indicated in parentheses with the first reference in thepaper.
Abstract is promotional in nature and not scientific.
Abstract does not contain data to support the conclusion of the study. This failure criterion applies to most typesof abstracts. However, it is not possible to present actual data in an abstract for some study types (for example,
some literature reviews, genomic studies, or bioinformatics). In such cases, lack of data does not lead torejection.
Abstract is a work in progress and there is no data available at the time of submission (excludes Trials in Progressabstracts).
Abstract - in its entirety – has been:o Submitted to and/or presented at another meeting.
▪ This is inclusive of meetings happening after the ASCPT 2024 Meeting and past ASCPT Meetings.
▪ Previously submitted abstracts with new data are acceptable to expand on the knowledge
gained.
o Published as a full research paper prior to presentation at the ASCPT 2024 Annual Meeting.

TRIALS IN PROGRESS ABSTRACTS
ASCPT recognizes the importance of enabling discussion on ongoing clinical trials, therefore, will consider this categoryof abstract for the ASCPT 2024 Annual Meeting. Trials in Progress abstracts presented during the ASCPT Annual Meeting
will provide researchers an opportunity to present ongoing trials, foster collaboration, and discuss novel trial design.
Trials in Progress are designated to abstracts that describe something novel within the application areas of ASCPT,providing “coming attractions” for clinical pharmacologists and translational scientists in practice. Abstracts submitted
as Trials in Progress should be ongoing without reportable results at the submission deadline. As such, Trials in Progressshould not include results.

Trial in Progress Abstract Submissions must:• Adhere to all submission guidelines of regular abstract submission with the primary difference being that noresults should be reported.
• Be organized into three sections:o Background▪ Scientific background/rationale for the trial▪ Trials in Progress abstract submissions should not be used to present preclinical or earlier-phaseclinical data for the first time. Preclinical and earlier-phase data that have been published can beincluded as a reference.
o Methods▪ Trial design and statistical methods, highlighting any novel aspects of the design.
▪ Major eligibility criteria without providing results or endpoints.
▪ Treatment or intervention planned.
▪ Major eligibility criteria, highlighting unusual aspects.
▪ Current enrollment without results or endpoints• Phase I studies may refer to “Cohort 1 and 2” etc.
• Phase II studies may refer to “x of X patients have been enrolled” etc.
• Phase III studies may refer to “The IRB last reviewed the trial in Month/Year andrecommended that the trial continue as planned.”▪ Patient enrollment must have begun or completed with no data analysis available by theabstract submission deadline. Exceptions will not be made to this criterion. Trials for which
patients have not yet been enrolled will be considered.
▪ The clinical trial registry number must be included in the abstract.
o Novelty of Design▪ How might this change clinical pharmacology or translational science?
FAILURE CRITERIA FOR TRIALS IN PROGRESS ABSTRACTS
Trial in Progress abstract submissions that contain any of the following will not be considered:• Preliminary data including toxicity, response rate, pharmacokinetic, or correlative analyses.
• Information about pricing, fees, or reimbursement related to trial participation.
• Proprietary drug names or names of drug manufacturers in the title or body of the abstract. Drug identifier(s)must be provided.
• Description of a common trial design with no novelty• Reportable results

TRAINEE ABSTRACT INFORMATION
Qualified ASCPT Member Student/Trainee authors with accepted abstracts for presentation can be considered for a
Presidential Trainee Award or a Student/Trainee Grant. A trainee is defined as a student, resident, or fellow currently
enrolled in a post-doctoral training program or who is pursuing a post-baccalaureate degree.
NOTE: If you are applying for both a Presidential Trainee Award and a Student/Trainee Grant, you can only be selected
for one of these opportunities. You will first be considered for the Presidential Trainee Award. If you do not receive theaward, we will proceed with your application for the Student/Trainee Grant.

Please hold on registering for the meeting until notification is sent for Presidential Trainee Awardees or aStudent/Trainee Grant Awardees in November 2023. If you register prior to being notified about a Presidential
Trainee Award or Student/Trainee Grant, ASCPT will not refund registration fees.
Presidential Trainee Award:••••

A $500 prize
Commemorative certificate
Complimentary registration for the Annual Meeting
Special recognition during the Annual Meeting

Out of the Presidential Trainees selected, the highest-scoring abstract will also receive the David J. Goldstein TraineeAward, and the second highest-scoring abstract will also receive the Jason Morrow Trainee Award. Both awards comewith an additional $1,000 prize.
Student/Trainee Grant
Thanks to the generosity of ASCPT donors, ASCPT is able to offer a limited number of Student/Trainee Grants for theASCPT 2024 Annual Meeting. Receiving this grant is contingent on attending the Annual Meeting, either in-person oronline.
The Student/Trainee grant will reimburse you up to $500 USD towards the cost of registration and/or travel expenses.
Reimbursement will be provided post-Annual Meeting.

ADDITIONAL ABSTRACT INFORMATION
Review and Notification
All abstracts will be peer reviewed and scored by members of the ASCPT Networks and Communities and by members ofthe Scientific Program Committee. Reviewers will use these Guidelines, including the failure criteria, to score theabstracts. All decisions are final and there is no appeal mechanism. Notifications will be sent by email in November
2023 to ONLY the presenting author.
Publication
Accepted abstracts will be published in the Abstract Supplement to Clinical Pharmacology & Therapeutics. Please be
sure to review your submission thoroughly – the abstracts will be published exactly as they are submitted. ASCPT will
not edit abstracts prior to publication.
Copyright
In consideration of the Society evaluating the Contribution for publication (and publishing the Contribution if the Society
so decides) the Author(s) grant to the Society for the full term of copyright and any extensions thereto, subject to clause
2 below, the exclusive right and irrevocable license:••

to edit, adapt, publish, reproduce, distribute, display, and store the Contribution in all forms, formats, and media
whether now known or hereafter developed (including without limitation in print, digital and electronic form)
throughout the world;
to license others to do any or all of the above.

Ownership of copyright remains with the Author(s).

EmbargoAcademic institutions, private organizations, and companies with products whose values may be influenced byinformation contained in an abstract may issue a press release to coincide with the abstract’s publication. However,information beyond that contained in the abstract, e.g., discussion of the abstract done as part of a scientific presentationor presentation of additional or new information that will be available at the time of the meeting, is embargoed until thestart of the ASCPT 2024 Annual Meeting. To assist in the promotion of abstracts prior to the Annual Meeting, ASCPT will
publish all abstract numbers, titles, and author details online as part of the scientific program prior to publication of theCPT supplement.
Information released prior to this day is a violation of the ASCPT Abstract Embargo Policy and may result in the abstract
being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying
financial and other sponsors about this policy.
Withdrawal
Only the presenting author may withdraw an abstract. Requests for withdrawals must be in writing tomeetings@ascpt.org with a copy to all authors.
Abstract Presentation
All abstract presenters are required to register for the Annual Meeting in the appropriate registration category(member, non-member, trainee/ student) and pay the applicable fees.
If for any reason the presenter is unable to attend the meeting, a substitution must be made with a person already listed
as an author on the abstract. The Society does not provide honoraria, travel, or housing reimbursement to attend theAnnual Meeting. Any abstract not presented during the Annual Meeting will be marked as “Withdrawn” in the abstract
supplement in Clinical Pharmacology & Therapeutics and online meeting program.
POSTER 2.0 INFORMATIONASCPT encourages all abstract presenters to utilize the ASCPT Board-approved Poster 2.0 format. The Poster 2.0
template uses less text for easier viewing and more efficient transfer of information.
Check out the Best of Poster 2.0’s winners from the 2023 Annual Meeting: Best of ASCPT 2023 Poster 2.0 (vimeo.com)
Presenters who wish to use the Poster 2.0 format must meet all criteria for the layout of information. Additionally, all
QR codes contained within submitted Poster 2.0s must lead to open science information. ASCPT staff will review
submissions to ensure adherence to these criteria. Any Poster 2.0 with a QR code that links to a pay wall will bewithdrawn from consideration at ASCPT 2024 Annual Meeting. Further details on Poster 2.0 will be provided inabstract notifications.
For more information on Poster 2.0 please check out this video or this infographic

Questions? Contact meetings@ascpt.org or (703) 836-6981, extension 108 or 109.